Related Experiment Video
Updated: Nov 12, 2025
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Larotrectinib: A Targeted Therapy for Solid Tumors
Gabriela Mota-George1, Susan M Schneider1
1Duke University.
Background:
Although neurotrophic tyrosine receptor kinase (NTRK) gene fusions are not common in most cancers, they are present in more than 90% of some rare tumors. The U.S. Food and Drug Administration has approved larotrectinib for patients with NTRK gene fusion-positive cancers that meet certain criteria. With ongoing advancements in tumor sequencing, it is anticipated that cancer treatment will be determined by genetic variants rather than by cancer type in the future.
Objectives:
This article provides an overview of larotrectinib, a targeted therapy.
Methods:
This article reviews clinical trial results and highlights implications for oncology nurses caring for patients taking larotrectinib.
Findings:
Larotrectinib is an effective treatment option for some patients with NTRK gene fusion-positive cancers. Oncology nurses are key to educating patients on dosing, administration, side effects, and precautions.
Insights
Larotrectinib is an effective targeted therapy for cancers with neurotrophic tyrosine receptor kinase (NTRK) gene fusions. Oncology nurses play a vital role in patient education for this treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare in most cancers but prevalent in certain rare tumor types.
- The U.S. Food and Drug Administration has approved larotrectinib for specific NTRK gene fusion-positive cancers.
- Future cancer treatment is expected to shift towards genetic variants over tumor histology.
Purpose of the Study:
- To provide an overview of larotrectinib, a targeted therapy.
- To review clinical trial results of larotrectinib.
- To highlight implications for oncology nurses.
Main Methods:
- Review of clinical trial data for larotrectinib.
- Analysis of treatment efficacy and patient outcomes.
- Identification of key nursing responsibilities in patient care.
Main Results:
- Larotrectinib demonstrates efficacy in treating patients with NTRK gene fusion-positive cancers.
- Oncology nurses are crucial for patient education regarding larotrectinib's dosing, administration, side effects, and precautions.
Conclusions:
- Larotrectinib represents a significant targeted treatment option for a specific subset of cancer patients.
- Effective patient education by oncology nurses is essential for optimal outcomes and safety when using larotrectinib.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
05:08Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
Published on: February 17, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...